A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes

Diabetes Care

Volumn 25, Issue 4, 2002, Pages 724-730

  Whitehouse, Fred ^a   Kruger, Davida F ^a   Fineman, Mark ^b   Shen, Larry ^b   Ruggles, James A ^b   Maggs, David G ^b   Weyer, Christian ^b   Kolterman, Orville G ^b  

^a HENRY FORD HOSPITAL   (United States)

^b AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; PLACEBO; PRAMLINTIDE; AMYLOID; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ANOREXIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MULTICENTER STUDY; NAUSEA; RANDOMIZED CONTROLLED TRIAL; TIME SERIES ANALYSIS; WEIGHT GAIN; WEIGHT REDUCTION; ADOLESCENT; ADULT; AGED; BLOOD; BODY WEIGHT; COMPARATIVE STUDY; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; FEMALE; INCIDENCE; MALE; MIDDLE AGED; PATIENT COMPLIANCE; STATISTICS;

ADOLESCENT; ADULT; AGED; AMYLOID; BODY WEIGHT; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PLACEBOS;

EID: 0036548068     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.25.4.724     Document Type: Article

References (29)

1. Atkinson MA, Maclaren NK: The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 331:1428-1436, 1994
2. Koda JE, Fineman M, Rink TJ, Dailey GE, Muchmore DB, Linarelli LG: Amylin concentrations and glucose control. Lancet 339:1179-1180, 1992
3. Klein R, Klein BE, Moss SE, Cruickshanks KJ: The medical management of hyperglycemia over a 10-year period in people with diabetes. Diabetes Care 19:744-750, 1996
4. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
5. Cryer PE, Binder C, Bolli GB, Cherrington AD, Gale EA, Gerich JE, Sherwin RS: Hypoglycemia in IDDM. Diabetes 38:1193-1199, 1989
6. Diabetes Control and Complications Trial Research Group: Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 46:271-286, 1997
7. The DCCT Research Group: Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial: the DCCT Research Group. Diabetes Care 11:567-573, 1988
8. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD: Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT: Diabetes Control and Complications Trial. JAMA 280:140-146, 1998
9. Weyer C, Maggs DG, Young AA, Kolterman OG: Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des 7: 1353-1373, 2001
10. Young A: Amylin's physiology and its role in diabetes. Curr Opin Endocrinol Diab 4:282-290, 1997
11. Young AA, Gedulin B, Vine W, Percy A, Rink TJ: Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 38:642-648, 1995
12. Young AA, Gedulin BR, Rink TJ: Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36)NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabolism 45:1-3, 1996
13. Gedulin BR, Rink TJ, Young AA: Dose-response for glucagonostatic effect of amylin in rats. Metabolism 46:67-70, 1997
14. Janes S, Gaeta L, Beaumont K, Beeley K, Rink T: The selection of pramlintide for clinical evaluation (Abstract). Diabetes 45: 235A, 1996
15. Samsom M, Szarka LA, Camilleri M, Vella A, Zinsmeister AR, Rizza RA: Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. Am J Physiol 278:G946-G951, 2000
16. Kong MF, Stubbs TA, King P, Macdonald IA, Lambourne JE, Blackshaw PE, Perkins AC, Tattersall RB: The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia 41:577-583, 1998
17. Nyholm B, Orskov L, Hove KY, Gravholt CH, Moller N, Alberti KG, Moyses C, Kolterman O, Schmitz O: The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism 48:935-941, 1999
18. Fineman MS, Koda SE, Shen LZ, Strobel SA, Maggs DG, Weyer C, Kolterman OG: The human amylin analog, pramlintide, corrects postprandial hyperglycemia in patients with type 1 diabetes. Metabolism (In Press)
19. Thompson RG, Peterson J, Gottlieb A, Mullane J: Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial. Diabetes 46:632-636, 1997
20. American Diabetes Association: Standards of medical care for patients with diabetes mellitus (Position Statement). Diabetes Care 24(Suppl. 1):S33-S43, 2001
21. Young AA, Crocker LB, Wolfe-Lopez D, Cooper GJS: Daily amylin replacement reverses hepatic glycogen depletion in insulin-treated streptozotocin diabetic rats. FEBS Lett 287:203-205, 1991
22. Levetan CS, Want LL: Impact of pramlintide on the amplitude of glycemic excursions (Abstract). Diabetes 50 (Suppl. 2): A501, 2001
23. Schmitz O, Nyholm B, Orskov L, Gravholt C, Moller N: Effects of amylin and the amylin agonist pramlintide on glucose metabolism. Diabet Med 14:519-523, 1997
24. Silvestre RA, Rodriguez-Gallardo J, Jodka C, Parkes DG, Pittner RA, Young AA, Marco J: Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas. Am J Physiol 280:E443-E449, 2001
25. Gedulin BR, Young AA: Hypoglycemia overrides amylin-mediated regulation of gastric emptying in rats. Diabetes 47:93-97, 1998
26. Nyholm B, Moller N, Gravholt CH, Orskov L, Mengel A, Bryan G, Moyses C, Alberti KGMM, Schmitz O: Acute effects of the human amylin analog AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 81:1083-1089, 1996
27. Reichard P, Pihl M: Mortality and treatment side-effects during long-term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes 43:313-317, 1994
28. Lutz TA, Mollet A, Rushing PA, Riediger T, Scharrer E: The anorelic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats. Int J Obes Relat Metab Discord 25:1005-1011, 2001
29. Rushing PA, Hagan MM, Seeley RJ, Lutz TA, D'Alessio DA, Air EL, Woods SC: Inhibition of central amylin signaling increases food intake and body adiposity in rats. Endocrinology 142:5035-5038, 2001